SMARCA2: A Potential Drug Target and Biomarker for SWI/SNF-Related Chromatin Subfamily A Member 2

Target Name: SMARCA2

NCBI ID: G6595

SMARCA2

SMARCA2: A Potential Drug Target and Biomarker for SWI/SNF-Related Chromatin Subfamily A Member 2

Introduction

Several chronic diseases, including cancer, are characterized by the accumulation of mutations in gene promoters, which lead to the activation of oncogenes and the inhibition of tumor suppressor genes. One of the key factors that contribute to this process is the interaction between stem cells ( SCs) and their surrounding environment, including the extracellular matrix (ECM) components. The study of these interactions is essential for the development of new therapeutic strategies for various diseases.

SMARCA2, a member of the SWI/SNF-related matrix-associated actin-dependent regulator (MADR) family, has been identified as a potential drug target and biomarker for SWI/SNF-related chromatin subfamily A member 2 (CSA2) mutations. Here , we will discuss the structure and function of SMARCA2, its potential as a drug target, and its potential as a biomarker for CSA2 mutations.

Structure and Function of SMARCA2

SMARCA2 is a 21-kDa protein that was identified as a new gene in the human genome using transcriptomics and genomic studies. SMARCA2 is localized to the nuclear envelope and is involved in the regulation of cellular processes, including cell adhesion, migration, and the cytoskeleton organization [2,3].

SMARCA2 is composed of multiple domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal T-cell receptor (TCR)-like domain [4,5]. The N-terminal transmembrane domain is responsible for the formation of a complex with the extracellular matrix (ECM) components, while the coiled-coil domain is involved in the regulation of the cytoskeleton organization and the formation of stress fibers [6,7].

SMARCA2 functions as a negative regulator of the SWI/SNF-related chromatin subfamily A member 2 (CSA2) gene, which encodes a protein involved in cell adhesion and migration [8,9]. The CSA2 gene is a tumor suppressor gene that is often mutated in various diseases, including cancer.

SMARCA2 is a critical regulator of CSA2 expression and function. The N-terminal transmembrane domain of SMARCA2 forms a complex with the ECM components, including the cytoskeleton and the extracellular matrix (ECM) components, which allows the regulation of cellular processes, including the cytoskeleton organization and the formation of stress fibers [6,7]. The coiled-coil domain of SMARCA2 is involved in the regulation of the cytoskeleton organization and the formation of stress fibers, which are critical for cell adhesion and migration [6,7].

SMARCA2 also contains a TCR-like domain that is involved in the regulation of cellular processes, including the cytoskeleton organization and the formation of stress fibers [6,7]. The TCR-like domain of SMARCA2 is critical for the regulation of CSA2 expression and function, as it interacts with the CSA2 gene [8,9].

Potential as a Drug Target

SMARCA2 has been identified as a potential drug target for various diseases, including cancer. The accumulation of mutations in the CSA2 gene has been linked to the development of various diseases, including cancer [11,12]. Therefore, targeting SMARCA2 as a drug target could be an effective strategy for the treatment of these diseases.

SMARCA2 has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and the cytoskeleton organization [6,7]. Therefore, targeting SMARCA2

Protein Name: SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2

Functions: Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Binds DNA non-specifically (PubMed:22952240, PubMed:26601204). Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity)

The "SMARCA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMARCA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets